Bicalutamide for early-stage bladder cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests whether the drug bicalutamide can help men with early-stage (non-invasive) bladder cancer, which has not grown into the bladder muscle. It is given before surgery to see if it can reduce the chance of the cancer coming back. Participants will be randomly assigned to receive bicalutamide or a placebo before their scheduled surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a male aged 18 or older.
- You must have suspected new or returning non-muscle-invasive bladder cancer (NMIBC) seen on cystoscopy or imaging, with no more than 2 prior episodes in the past 18 months.
- You must have had a CT or MRI scan of your abdomen and pelvis within the last 6 months showing no signs of cancer spread.
- You must be considered healthy enough for bladder surgery by your urologist.
- You must not have had certain hormone treatments (like Lupron, Casodex, or finasteride) in the past 6 months, and you must not be taking the blood thinner warfarin.
- You must not have had prior pelvic radiation, or a history of muscle-invasive bladder cancer, or certain other bladder cancers, and you must not have had BCG treatment in the past 2 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new form of intravesical (given directly into the bladder) treatment called rMBCG for people with non-muscle invasive bladder cancer who have not had BCG therapy before. It may be an option for those with certain types of early bladder cancer, including carcinoma in situ (CIS) or papillary tumors after removal surgery.
This trial tests STM-416, given around the time you have surgery to remove recurring bladder tumors, to see if it can reduce the chance the cancer comes back. It is for people with high-risk early bladder cancer (non–muscle-invasive) who have already had standard treatment and now need another TURBT.
This trial studies whether bicalutamide can improve outcomes for people with non-muscle-invasive bladder cancer who are starting BCG through the bladder. It may help prevent cancer from coming back or progressing after BCG.
This study tests a urine test that may help find bladder cancer early without needing invasive procedures. It is for people with high-grade or high-risk non-muscle-invasive bladder cancer who are receiving or have received BCG treatment.
This trial tests a tiny device placed into bladder tumors before surgery to see which drugs might work best for each patient, helping guide future treatment choices.
This study tests a new way to give a chemotherapy drug during bladder surgery to help stop the cancer from returning. It is for people with a type of bladder cancer that has not spread into the muscle.
Hear when a new Non-Muscle Invasive Bladder Urothelial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.